Why the study?
Atherosclerosis is driven by inflammatory and metabolic dysregulation involving adipose tissue-derived adipokines, but phenotype-specific quantitative associations between circulating adipokines and carotid atherosclerosis required evaluation.
Are circulating adipokine levels associated with carotid atherosclerosis phenotypes in adults?
Are circulating adipokine levels associated with carotid atherosclerosis phenotypes in adults?
Circulating adipokines such as omentin, adiponectin, and leptin show phenotype-specific associations with carotid atherosclerosis and may serve as biomarkers.
Answers are grounded in this paper and cite their sources.
May support adipokine profiling for CA phenotyping in research; leaves open clinical adoption pending causal validation.
Background Atherosclerosis (AS) is driven by inflammatory and metabolic dysregulation. Carotid atherosclerosis (CA), assessable by ultrasonographic carotid intima–media thickness (cIMT) and plaque, provides a noninvasive window into AS. Adipose tissue–derived adipokines are involved in AS. Aim We conducted a phenotype-specific systematic review and meta-analysis of observational studies to quantify associations between circulating adipokines and CA. Methods Following a preregistered protocol, PubMed, Embase, and Web of Science were searched. Adults with ultrasound-defined CA (increased cIMT and/or carotid plaque) and controls were included. Mean and standard deviation (SD) of circulating adipokines were extracted and converted to standardized mean difference (SMD) for pooled analysis. Results Nineteen studies (n = 5860; Asia/Europe/Americas; 8 cross-sectional, 8 case-control, 3 cohort) were included for quantitative analysis. In the increased cIMT phenotype, adiponectin was lower in CA [SMD = −0.72 (−1.00, −0.44), P < 0.05], whereas in the plaque phenotype it was higher [SMD = 0.29 (0.11, 0.47), P < 0.05]. Leptin was higher in CA, reaching significance in the plaque phenotype [SMD = 0.70 (0.13, 1.28), P = 0.02]. Omentin was consistently lower in CA across phenotypes [SMD = −1.43 (−2.20, −0.66), P < 0.001]. Sensitivity analysis supported robustness for adiponectin (stronger effects after excluding healthy cohorts), and publication-bias assessment was feasible only for adiponectin and were negative. Conclusions This study indicated that circulating adipokine levels can serve as phenotype-specific biomarkers in CA.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: